Eosinophilic Gastroenteritis Treatment Market 2032: Key Clinical Trials, FDA Approvals, Therapies, Prevalence, and Companies - DelveInsight | Novartis, Allakos, AstraZeneca, Pfizer, Regeneron, Celgene, more

(Albany, USA) DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Eosinophilic Gastroenteritis, historical and forecasted epidemiology as well as the Eosinophilic Gastroenteritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Eosinophilic Gastroenteritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Gastroenteritis Market Forecast
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Eosinophilic Gastroenteritis Market Report:
• The Eosinophilic Gastroenteritis market size was valued approximately USD 78 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• More than 31,000 cases of Eosinophilic Gastroenteritis were reported in the US in 2021, but only about 2,800 cases were reported in Spain
• In the United States in 2021, there were approximately 16,500 males and 15,000 females who had eosinophilic gastroenteritis. By 2032, the prevalence is anticipated to rise
• In 2021, Germany had the most common incidence of eosinophilic gastroenteritis among the EU5 nations (about 4,400 cases)
• Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
• Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 μg/mL, RPC4046, OC000459, and others
• The Eosinophilic Gastroenteritis epidemiology based on gender analyzed that Eosinophilic Gastroenteritis shows slight predominance in males than females in the US. However, in eosinophilic esophagitis (EoE), there is no male predominance
• The Eosinophilic Gastroenteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Gastroenteritis pipeline products will significantly revolutionize the Eosinophilic Gastroenteritis market dynamics.
• On August 2024, Regeneron Pharmaceuticals announced results of a Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
• On January 2024, Allakos Inc. announced results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
• On January 2024, Celgene announced results of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis

Eosinophilic Gastroenteritis Overview
Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition characterized by an abnormal accumulation of eosinophils, a type of white blood cell, in the gastrointestinal (GI) tract. This disorder can affect any part of the GI tract, from the esophagus to the colon, and its symptoms vary depending on the location and depth of eosinophil infiltration. Common symptoms include abdominal pain, nausea, vomiting, diarrhea, weight loss, and in severe cases, intestinal obstruction or perforation.
Eosinophilic Gastroenteritis is thought to result from an abnormal immune response, often associated with food allergies, environmental allergens, or other atopic conditions like asthma or eczema. The diagnosis of Eosinophilic Gastroenteritis typically involves a combination of clinical evaluation, endoscopic procedures, and biopsy, which reveal elevated eosinophil counts in the GI tissue.
Management of Eosinophilic Gastroenteritis primarily focuses on reducing inflammation and controlling symptoms. Dietary modifications, such as elimination diets to identify and avoid triggering foods, are often the first line of treatment. Pharmacological therapies include corticosteroids to reduce inflammation and immunomodulators to control the immune response. In some cases, biologic agents targeting specific pathways involved in eosinophil activation and recruitment may be used.
Despite its chronic nature, ongoing research into the pathophysiology of Eosinophilic Gastroenteritis and advancements in targeted therapies offer hope for improved management and outcomes for patients with this challenging condition.

Get a Free sample for the Eosinophilic Gastroenteritis Market Report
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Eosinophilic Gastroenteritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Eosinophilic Gastroenteritis Epidemiology Segmentation:
The Eosinophilic Gastroenteritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Eosinophilic Gastroenteritis
• Prevalent Cases of Eosinophilic Gastroenteritis by severity
• Gender-specific Prevalence of Eosinophilic Gastroenteritis
• Diagnosed Cases of Episodic and Chronic Eosinophilic Gastroenteritis

Download the report to understand which factors are driving Eosinophilic Gastroenteritis epidemiology trends @ Eosinophilic Gastroenteritis Epidemiology Forecast
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Eosinophilic Gastroenteritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Gastroenteritis market or expected to get launched during the study period. The analysis covers Eosinophilic Gastroenteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Eosinophilic Gastroenteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Eosinophilic Gastroenteritis Therapies and Key Companies
• Lirentelimab: Allakos
• Benralizumab: AstraZeneca
• INVA8001: Invea Therapeutics
• Etrasimod: Pfizer
• reslizumab: Ception Therapeutics
• Dupilumab: Regeneron
• ESO-101: EsoCap AG
• CC-93538: Celgene
• AK002: Allakos Inc.
• APT-1011: Ellodi Pharma
• budesonide: Takeda
• Mesalamine: Dr. Falk Pharma GmbH
• IRL201104: Revolo Biotherapeutics
• QAX576: Novartis
• Florence 30 μg/mL: EMS
• RPC4046: Celgene
• OC000459: Oxagen Ltd

Discover more about therapies set to grab major Eosinophilic Gastroenteritis market share @ Eosinophilic Gastroenteritis Treatment Market
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Eosinophilic Gastroenteritis Market Drivers
• Increasing disease burden due to increasing prevalence in the general population
• A better understanding of disease pathogenesis may lead to the identification of novel molecular targets for the treatment

Eosinophilic Gastroenteritis Market Barriers
• Lack of approved therapies indicated for EGE in the US, EU, and Japan
• Huge annual psychological, social, and economic burden (QALY), in advanced countries, due to EGE

Scope of the Eosinophilic Gastroenteritis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
• Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 μg/mL, RPC4046, OC000459, and others
• Eosinophilic Gastroenteritis Therapeutic Assessment: Eosinophilic Gastroenteritis current marketed and Eosinophilic Gastroenteritis emerging therapies
• Eosinophilic Gastroenteritis Market Dynamics: Eosinophilic Gastroenteritis market drivers and Eosinophilic Gastroenteritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Eosinophilic Gastroenteritis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Gastroenteritis Market Access and Reimbursement

To know more about Eosinophilic Gastroenteritis companies working in the treatment market, visit @ Eosinophilic Gastroenteritis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Eosinophilic Gastroenteritis Market Report Introduction
2. Executive Summary for Eosinophilic Gastroenteritis
3. SWOT analysis of Eosinophilic Gastroenteritis
4. Eosinophilic Gastroenteritis Patient Share (%) Overview at a Glance
5. Eosinophilic Gastroenteritis Market Overview at a Glance
6. Eosinophilic Gastroenteritis Disease Background and Overview
7. Eosinophilic Gastroenteritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Eosinophilic Gastroenteritis
9. Eosinophilic Gastroenteritis Current Treatment and Medical Practices
10. Eosinophilic Gastroenteritis Unmet Needs
11. Eosinophilic Gastroenteritis Emerging Therapies
12. Eosinophilic Gastroenteritis Market Outlook
13. Country-Wise Eosinophilic Gastroenteritis Market Analysis (2019-2032)
14. Eosinophilic Gastroenteritis Market Access and Reimbursement of Therapies
15. Eosinophilic Gastroenteritis Market Drivers
16. Eosinophilic Gastroenteritis Market Barriers
17. Eosinophilic Gastroenteritis Appendix
18. Eosinophilic Gastroenteritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Report :
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-nec-epidemiology-forecast
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.